Zetta Genomics gains £2.5m seed funding to realise the power of genomic data in precision medicine
Summary
Nina Capital, APEX Medical and Cambridge Enterprise invest in transformational open-source data technology – to deliver precision medicine at scale LONDON, UK. The successful round secures leading global Venture Capital (VC) investment in the company’s XetaBase platform – a transformational genomic data management technology that powers the discovery and delivery of precision medicine at scale. Marc Subirats, Partner at lead investor, Nina Capital, said, “Genomic medicine has enjoyed explosive growth in the past five years, but this is set to be eclipsed in the next decade. Microsoft, for example, selected Zetta Genomics for its Reactor programme – identified as a company of high value potential – providing tailored support across its services, including the Azure cloud platform. Zetta’s technology helps researchers and clinicians fully exploit genomic data, speeding the delivery of precision medicine across the world.” VC-backed funding will focus on growth, enhancing the company’s partnership network while it expands from the UK to open both Spanish and US offices.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
